NCT02399215View on ClinicalTrials.gov

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 15, 2015

Primary Completion Date

September 1, 2019

Study Completion Date

August 31, 2022

Conditions
Carcinoid TumorMetastatic Carcinoid TumorNeuroendocrine Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nintedanib

Given PO

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER

NCT02399215 - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter